Lung Cancer Treatment Drugs Market Report 2024 (Global Edition)

Global Lung Cancer Treatment Drugs Market Report 2024 Market Size Split by Cancer Type (NSCLC, SCLC), by Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy, Othe...

Lung Cancer Treatment Drugs Market Report Description

We have various report editions of Lung Cancer Treatment Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Lung Cancer Treatment Drugs Market Insights Video

Competitive Landscape of the Lung Cancer Treatment Drugs Market

In the Lung Cancer Treatment Drugs market's competitive landscape, numerous key competitors are driving innovation and growth. In an effort to broaden their product portfolio and enhance their geographical presence in response to the demand for lung cancer therapeutics, players are employing a variety of strategies. Partnerships and alliances, product innovation, and mergers are among the primary strategies implemented by participants in the global lung cancer therapeutics market.

In November 2022, The FDA approved the combination of platinum-based chemotherapy and tremelimumab (Imjudo) with durvalumab (Imfinzi) for the treatment of metastatic non-small cell lung cancer (NSCLC) in the absence of EGFR or ALK mutations. This approval was predicated on the POSEIDON study, which demonstrated substantial enhancements in progression-free survival and overall survival when contrasted with platinum-based chemotherapy alone. Common adverse effects included fatigue, nausea, musculoskeletal pain, and a reduced appetite. The approval represents a substantial improvement in the treatment of NSCLC, providing patients with more effective therapeutic alternatives. (Source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non) In November 2023, Augtyro™ (repotrectinib) was approved by the FDA for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This next-generation tyrosine kinase inhibitor (TKI) was approved on the basis of the TRIDENT-1 trial, which demonstrated a high objective response rate and durable responses, while targeting ROS1 oncogenic fusions. Bristol Myers Squibb's dedication to precision medicine is underscored by the addition of Augtyro to their NSCLC portfolio. (Source: https://news.bms.com/news/corporate-financial/2023/US-Food-and-Drug-Administration-Approves-Augtyro/default.aspx) In October 2024, For adults with resectable non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, the FDA has approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for neoadjuvant treatment. Single-agent Opdivo is then administered as adjuvant therapy after surgery. The CheckMate-77T trial, which demonstrated a significantly higher pathologic complete response rate and a significantly longer event-free survival rate than chemotherapy alone, was the basis for this approval. (Source: https://news.bms.com/news/corporate-financial/2024/U.S.-Food-and-Drug-Administration-Approves-Perioperative-Treatment-of-Neoadjuvant-Opdivo-nivolumab-and-Chemotherapy-Followed-by-Surgery-and-Adjuvant-Single-Agent-Opdivo-for-Resectable-Non-Small-Cell-Lung-Cancer-NSCLC/default.aspx)

Top Companies Market Share in Lung Cancer Treatment Drugs Industry: (In no particular order of Rank)

• Pfizer
• AstraZeneca
• Merck (MSD)
• Bristol-Myers Squibb
• Eli Lilly and Company
• Boehringer Ingelheim
• Novartis
• Merck KGaA (EMD Serono)
• AbbVie
• Takeda
• Astellas Pharma
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Johnson & Johnson
• Sanofi
• Amgen.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Lung Cancer Treatment Drugs Market

Which Region Dominates the Lung Cancer Treatment Drugs Market in 2024?

According to Cognitive Market Research, North America currently dominates the Lung Cancer Treatment Drugs market, and the region is expected to have significant growth during the projected period. Awareness of lung cancer risks and symptoms has improved due to public health campaigns, education, and non-profit lobbying. This awareness encourages people to seek medical advice and get regular tests, which speeds up diagnosis and treatment.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Governments and healthcare institutions are making substantial investments in the fight against pollution-related diseases, which is facilitating the growth of the lung cancer treatment market in the region.

The current report Scope analyzes Lung Cancer Treatment Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Lung Cancer Treatment Drugs

According to Cognitive Market Research, the global Lung Cancer Treatment Drugs market size was estimated at USD 40258.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 16103.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Lung Cancer Treatment Drugs market with a market size of USD 12705.58 million in 2024 and is anticipated to grow at a CAGR of 8.5% during the projected period. The U.S. market's continuous technological advancements and a high rate of adoption of new therapies.
• The Canada Lung Cancer Treatment Drugs market had a market share of USD 1932.41 million in 2024 and is anticipated to grow at a CAGR of 9.5% during the projected period. Canada’s government investment in healthcare infrastructure and innovation.
• The Mexico Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 9.2% during the projected period, with a market size of USD 1465.41 million in 2024.

Europe Lung Cancer Treatment Drugs

According to Cognitive Market Research, the global Lung Cancer Treatment Drugs market size was estimated at USD 40258.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 12077.55 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2031.

• The United Kingdom Lung Cancer Treatment Drugs market had a market share of USD 2029.03 million in 2024 and is anticipated to grow at a CAGR of 9.8% during the projected period. In the UK, Lung Cancer Treatment Drugs sales see an upswing due to the support it receives from foreign investments.
• The France Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 8.2% during the projected period, with a market size of USD 1111.13 million in 2024.
• According to Cognitive Market Research, the German Lung Cancer Treatment Drugs market size was valued at USD 2391.35 million in 2024 and is anticipated to grow at a CAGR of 9.2% during the projected period. In Germany, Lung Cancer Treatment Drugs surged due to country's robust economic policies and investment in healthcare research and development that are responsible for the adoption of new treatment modalities.
• The Italy Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 8.4% during the projected period, with a market size of USD 1038.67 million in 2024.
• The Russia Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 8.0% during the projected period, with a market size of USD 1872.02 million in 2024.
• The Spain Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 8.1% during the projected period with a market size of USD 990.36 million in 2024
• The Luxembourg Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 9.1% during the projected period, with a market size of USD 374.40 million in 2024.
• The Portugal Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 8.8% during the projected period, with a market size of USD 253.63 million in 2024.
• The Greece Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 9.3% during the projected period, with a market size of USD 144.93 million in 2024.
• The Rest of Europe's Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 7.7% during the projected period, with a market size of USD 1872.02 million in 2024.

Asia Pacific Lung Cancer Treatment Drugs

According to Cognitive Market Research, the global Lung Cancer Treatment Drugs market size was estimated at USD 40258.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 9259.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Lung Cancer Treatment Drugs market size was valued at USD 4166.75 million in 2024 and is anticipated to grow at a CAGR of 12.0% during the projected period. Lung Cancer Treatment Drugs surged in China due to large population and rising incidence of lung cancer.
• The Japan Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 11.0% during the projected period, with a market size of USD 1277.80 million in 2024.
• The India Lung Cancer Treatment Drugs market had a market share of USD 1111.13 million in 2024 and is anticipated to grow at a CAGR of 14.3% during the projected period. India's government capital expenditure and robust domestic demand.
• The South Korean Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 11.6% during the projected period, with a market size of USD 925.95 million in 2024.
• The Australian Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 12.2% during the projected period, with a market size of USD 481.49 million in 2024.
• The South East Asia Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 13.5% during the projected period, with a market size of USD 638.90 million in 2024.
• The Rest of Asia Pacific Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 12.3% during the projected period, with a market size of USD 657.42 million in 2024.

South America Lung Cancer Treatment Drugs

According to Cognitive Market Research, the global Lung Cancer Treatment Drugs market size was estimated at USD 40258.5 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 2012.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Lung Cancer Treatment Drugs market size was valued at USD 861.53 million in 2024 and is anticipated to grow at a CAGR of 10.5% during the projected period. Lung Cancer Treatment Drugs flourished in Brazil due to healthcare infrastructure and increase consumer spending.
• Argentina's Lung Cancer Treatment Drugs market had a market share of USD 338.17 million in 2024 and is anticipated to grow at a CAGR of 10.8% during the projected period. Argentina's improving healthcare infrastructure guarantees improved patient outcomes and stimulates market demand.
• Colombia Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 9.7% during the projected period, with a market size of USD 179.15 million in 2024.
• Peru Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 10.1% during the projected period, with a market size of USD 165.06 million in 2024.
• Chile Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 10.2% during the projected period, with a market size of USD 144.93 million in 2024.
• The Rest of Latin America's Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 9.0% during the projected period, with a market size of USD 324.08 million in 2024.

Middle East and Africa Lung Cancer Treatment Drugs

According to Cognitive Market Research, the global Lung Cancer Treatment Drugs market size was estimated at USD 40258.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 805.17 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031..

• The GCC Countries Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 11.0% during the projected period, with a market size of USD 344.61 million in 2024. Lung Cancer Treatment Drugs sales flourish due to Oil and gas exports, government investments, and infrastructure development.
• The Egypt Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 10.5% during the projected period, with a market size of USD 84.54 million in 2024.
• The South Africa Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 11.2% during the projected period, with a market size of USD 127.22 million in 2024. Lung Cancer Treatment Drugs sales flourished in South Africa due to enhance healthcare access and infrastructure.
• The Turkey Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 9.7% during the projected period, with a market size of USD 69.24 million in 2024.
• The Nigeria Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 9.3% during the projected period, with a market size of USD 84.54 million in 2024.
• The Rest of the MEA Lung Cancer Treatment Drugs market is anticipated to see growth at a CAGR of 9.2% during the projected period, with a market size of USD 95.01 million in 2024.

Lung Cancer Treatment Drugs Market Analysis

Lung Cancer Treatment Drugs Market Cancer Type Segment Analysis

According to Cognitive Market Research, NSCLC are likely to dominate the Lung Cancer Treatment Drugs Market over the forecast period. It is because of the increased incidence of non-small cell lung cancer (NSCLC) as well as the ongoing development of targeted treatments and personalized therapy for this form of cancer that this considerable proportion has been achieved.

The SCLC is the fastest-growing segment in the Lung Cancer Treatment Drugs Market. SCLC is an aggressive form of lung cancer that necessitates immediate and intensive treatment, resulting in an increased demand for effective therapies. Furthermore, the treatment of SCLC has been shown to be promising by recent developments in immunotherapies and targeted therapies, which has resulted in a surge in investment and research in this field.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Lung Cancer Treatment Drugs Industry. Request a Free Sample PDF!

Lung Cancer Treatment Drugs Market Treatment Type Segment Analysis

According to Cognitive Market Research, the Chemotherapy segment holds the largest share of the market, owing to the fact that it has been used for a long time and has shown to be helpful in treating a variety of lung cancers, including non-small cell lung cancer and small cell lung cancer.

In the Lung Cancer Treatment Drugs Market, the Immunotherapy sector has been expanding at a rapid pace. due to its capacity to utilize the body's immune system to combat cancer cells, resulting in enhanced patient outcomes and survival rates. The accelerated expansion of this field is being driven by the ongoing research and development in immunotherapy treatments and the increasing adoption of these treatments.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Lung Cancer Treatment Drugs End-user Segment Analysis

Lung Cancer Treatment Drugs Market End-user Segment Analysis

According to Cognitive Market Research, The Hospitals segment holds the largest market share as a result of their extensive infrastructure, an abundance of cutting-edge treatment choices, and the capacity to provide multidisciplinary care to patients suffering from lung cancer.

In the Lung Cancer Treatment Drugs market, the rapidly growing sector is the Cancer & Radiation Therapy Centers. The growth in this category is due to a growing need for personalized care in oncology, advancements in radiation treatment technologies, and the increasing emphasis on specialized and targeted cancer therapies.

• Hospitals
• Cancer & Radiation Therapy Centers
• Others

Lung Cancer Treatment Drugs Therapy Segment Analysis

Lung Cancer Treatment Drugs Market Therapy Segment Analysis

According to Cognitive Market Research, the Chemotherapy segment dominates the market, owing to the fact that it has been used for a long time and has shown to be helpful in treating a variety of lung cancers, consisting non-small cell lung cancer and small cell lung cancer.

Immunotherapy is projected to be the fastest-growing segment in the Lung Cancer Treatment Drugs market, due to its capacity to utilize the body's immune system to combat cancer cells, resulting in enhanced patient outcomes and survival rates. The rapid expansion of this field is being driven by the ongoing research and development in immunotherapy treatments and their increasing adoption.

• Targeted Therapy
• Immunotherapy
• Chemotherapy

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion